Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Device lets Parkinson’s patients track their own motor symptoms

Stanford University researchers developed a simple, portable device that allows Parkinson’s disease patients to monitor their motor symptoms remotely, in real time, providing their doctors with updated information that can be used to guide treatment decisions. Patients tap alternating fingers for 30 seconds on the two-lever device, called KeyDuo, which…

Trial testing Parkinson’s disease-modifying therapy hits milestone

Herantis Pharma announced that its Phase 1b clinical trial evaluating the safety and preliminary efficacy of HER-096, a potential disease-modifying therapy for Parkinson’s disease, has hit a key milestone: All dosing regimens and follow-up clinic visits have been completed. Top-line results from the trial (NCT06659562, EUCT2024-512532-30-00) —…

AI pen analyzes handwriting to spot Parkinson’s with 96% accuracy

A low-cost, self-powered pen with magnetic ink may help detect early signs of Parkinson’s disease by analyzing handwriting. When the pen was tested, it was able to distinguish Parkinson’s patients from healthy people with an average accuracy of 96%, a study reports. “Detection of subtle motor symptoms unnoticeable to…

Copper supplementation shows promise in Parkinson’s mice

Copper supplementation that reaches the brain reduces the signs and symptoms of Parkinson’s disease in a mouse model, a study found. Researchers found that copper restored the function of SOD1, an antioxidant enzyme that’s prone to misfolding and forming toxic clumps, impairing the function of dopamine-producing nerve cells that…

Casma to develop CSM-101 as treatment for Parkinson’s

Casma Therapeutics said it will develop CSM-101 as a potential disease-modifying oral treatment for people with Parkinson’s disease and Gaucher disease. CSM-101 is a first-in-class small molecule designed to activate the calcium channel TRPML1, a key regulator of lysosomal function and autophagy, a process in which cells deliver…

Distinct immune responses may detect Parkinson’s before symptoms

People in the presymptomatic stages of Parkinson’s disease have distinct patterns of stimulated immune responses relative to those with clinically diagnosed disease or individuals who do not have Parkinson’s, according to a new study. In particular, the release of certain immune signaling proteins from isolated and stimulated immune cells…

New test for Parkinson’s disease shows 95% accuracy: Study

A newly developed test was able to distinguish — with an accuracy of 95% — between individuals with and without Parkinson’s disease, using samples of cerebrospinal fluid (CSF), the liquid surrounding the brain and spinal cord, according to a new study from Germany. The researchers noted that Parkinson’s often…

Different exercises may ease specific Parkinson’s symptoms

Different types of exercise can have different effects on Parkinson’s disease, a study suggests. For instance, tai chi or at-home bodyweight strength training can improve motor function, while tai chi or strength training with elastic bands and dumbbells can help ease freezing of gait. At the same time, home-based…